SageView Advisory Group
RNAC icon

SageView Advisory Group’s Cartesian Therapeutics RNAC Stock Holding History

SageView Advisory Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3
Closed -$22 – 2036
2025
Q4 		$22 Buy
+3
New +$24 ﹤0.01% 2586

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SageView Advisory Group's RNAC Position: Q1 2026 in Review

SageView Advisory Group sold out of Cartesian Therapeutics (RNAC) in Q1 2026, closing a stake of 3 shares — an estimated $22 sold.

SageView Advisory Group first reported a position in RNAC in Q4 2025 and held it in 1 quarter. The position peaked at $22 in Q4 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • SageView Advisory Group reported no remaining Cartesian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 3 Cartesian Therapeutics shares in Q1 2026, an estimated $22.
  • SageView Advisory Group first reported a position in Cartesian Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Cartesian Therapeutics position peaked at $22 in Q4 2025.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.